CY1110397T1 - Πολυπεπτιδιο που εχει βελτιωμενη δραστικοτητα αποαμινασης κυτοσινης - Google Patents

Πολυπεπτιδιο που εχει βελτιωμενη δραστικοτητα αποαμινασης κυτοσινης

Info

Publication number
CY1110397T1
CY1110397T1 CY20081101026T CY081101026T CY1110397T1 CY 1110397 T1 CY1110397 T1 CY 1110397T1 CY 20081101026 T CY20081101026 T CY 20081101026T CY 081101026 T CY081101026 T CY 081101026T CY 1110397 T1 CY1110397 T1 CY 1110397T1
Authority
CY
Cyprus
Prior art keywords
activity
polyperptide
disinsectivity
cytosin
improved
Prior art date
Application number
CY20081101026T
Other languages
English (en)
Inventor
Philippe Erbs
Original Assignee
Transgene S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene S.A. filed Critical Transgene S.A.
Publication of CY1110397T1 publication Critical patent/CY1110397T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins

Abstract

Η παρούσα εφεύρεση αφορά πολυπεπτίδιο που έχει δραστικότητα Cdάσης, που χαρακτηρίζεται από το ότι λαμβάνεται από μία φυσική Cdάση με προσθήκη μίας αλληλουχίας αμινοξέος, υπό την προϋπόθεση ότι το εν λόγω πολυπεπτίδιο δεν έχει δραστικότητα UPRτάσης ή Κινάσης Θυμιδίνης.
CY20081101026T 2003-07-21 2008-09-22 Πολυπεπτιδιο που εχει βελτιωμενη δραστικοτητα αποαμινασης κυτοσινης CY1110397T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03360087 2003-07-21
US50827403P 2003-10-06 2003-10-06
EP04744156A EP1649023B1 (en) 2003-07-21 2004-06-29 Polypeptide having an improved cytosine deaminase activity

Publications (1)

Publication Number Publication Date
CY1110397T1 true CY1110397T1 (el) 2015-04-29

Family

ID=39719832

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081101026T CY1110397T1 (el) 2003-07-21 2008-09-22 Πολυπεπτιδιο που εχει βελτιωμενη δραστικοτητα αποαμινασης κυτοσινης

Country Status (17)

Country Link
US (3) US7790445B2 (el)
EP (2) EP1897938B9 (el)
JP (1) JP4672659B2 (el)
KR (1) KR101062140B1 (el)
CN (1) CN1826410B (el)
AT (1) ATE405654T1 (el)
AU (1) AU2004257935B2 (el)
CA (1) CA2532783C (el)
CY (1) CY1110397T1 (el)
DE (1) DE602004015995D1 (el)
DK (1) DK1649023T3 (el)
ES (1) ES2311831T3 (el)
HK (2) HK1112024A1 (el)
IL (1) IL173158A (el)
PL (1) PL1649023T3 (el)
PT (1) PT1649023E (el)
WO (1) WO2005007857A1 (el)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2029756T3 (en) 2006-06-20 2017-02-13 Transgene Sa PROCEDURE FOR PREPARING POXVIRA AND POXVIRUS COMPOSITIONS
ES2618490T3 (es) 2007-07-03 2017-06-21 Transgene Sa Estirpes celulares aviares inmortalizadas
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
EA027693B1 (ru) * 2008-09-26 2017-08-31 Токаджен Инк. Рекомбинантный репликационно-компетентный ретровирус с цитозиндезаминазной активностью для генной терапии нарушений клеточной пролиферации
CA2760465A1 (en) 2009-05-12 2010-11-18 Transgene Sa Method for orthopoxvirus production and purification
EP2456461A1 (en) 2009-07-21 2012-05-30 Transgene SA Enzymatic composition for the digestion of chicken embryos
EP2527432A1 (en) * 2011-05-23 2012-11-28 Novozymes A/S Bi-directional cytosine deaminase-encoding selection marker
WO2013004658A1 (en) 2011-07-01 2013-01-10 Transgene Sa Formulations of 5-fluorocytosine and uses thereof.
US9642921B2 (en) 2012-12-20 2017-05-09 Tocagen Inc. Cancer combination therapy and recombinant vectors
CN106413726B (zh) 2014-04-10 2020-07-24 特朗斯吉有限公司 痘病毒溶瘤载体
PL3169341T3 (pl) 2014-07-16 2019-12-31 Transgene Sa Wirus onkolityczny do ekspresji modulatorów punktu kontroli immunologicznej
DK3226894T3 (da) 2014-12-01 2019-10-21 Transgene Sa Stabile flydende vacciniavirus-formuleringer
EP3256156A1 (en) * 2015-02-13 2017-12-20 Transgene SA Immunotherapeutic vaccine and antibody combination therapy
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
US20190336552A1 (en) 2016-05-30 2019-11-07 Astellas Pharma Inc. Genetically engineered vaccinia viruses
US10888594B2 (en) * 2016-05-30 2021-01-12 National University Corporation Tottori University Genetically engineered vaccinia viruses
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
MX2020009262A (es) 2018-03-07 2021-01-08 Transgene Vectores de parapoxvirus.
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
SG11202103097QA (en) 2018-09-26 2021-04-29 Astellas Pharma Inc Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2024038175A1 (en) 2022-08-18 2024-02-22 Transgene Chimeric poxviruses

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
FR2583429B1 (fr) * 1985-06-18 1989-11-03 Transgene Sa Vecteur d'expression de l'interferon u dans les cellules de mammifere, procede pour sa mise en oeuvre et produit obtenu et composition pharmaceutique contenant l'interferon u
CA2018273C (en) 1989-06-09 1999-04-06 Peter D. Senter Thermally stable cytosine deaminase
US5358866A (en) 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
DE69417734T2 (de) 1993-02-16 1999-10-07 Onyx Pharma Inc Cytopathische viren zur therapie und prophylaxe der neoplasie
WO1994028143A1 (en) * 1993-05-21 1994-12-08 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
FR2722208B1 (fr) 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
US5856153A (en) 1994-11-17 1999-01-05 Cayla Suicide genes and new associations of pyrimidine nucleobase and nucleoside analogs with new suicide genes for gene therapy of acquired diseases
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
FR2737222B1 (fr) 1995-07-24 1997-10-17 Transgene Sa Nouveaux vecteurs viraux et lignee pour la therapie genique
FR2759382A1 (fr) 1997-02-10 1998-08-14 Transgene Sa Nouveaux composes et compositions les contenant utilisables pour le transfert d'au moins une substance therapeutiquement active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique
FR2762615B1 (fr) 1997-04-28 1999-07-16 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes et vecteur le contenant
FR2777570A1 (fr) 1998-04-17 1999-10-22 Transgene Sa Mutant ayant une activite phosphoribosyl transferase
US6552005B1 (en) * 1998-09-29 2003-04-22 Uab Research Foundation Molecular chemotherapy enhancement of radiotherapy
US20030121068A1 (en) * 2001-11-30 2003-06-26 Paul Orchard Vector encoding suicide and marker constructs
US7141404B2 (en) * 2002-12-27 2006-11-28 Onyx Pharmaceuticals, Inc. Candida kefyr cytosine deaminase

Also Published As

Publication number Publication date
AU2004257935B2 (en) 2009-11-19
KR101062140B1 (ko) 2011-09-05
EP1649023A1 (en) 2006-04-26
HK1112024A1 (en) 2008-08-22
PL1649023T3 (pl) 2009-01-30
CN1826410B (zh) 2011-10-26
EP1897938B9 (en) 2011-08-31
ATE405654T1 (de) 2008-09-15
US8257692B2 (en) 2012-09-04
JP2006527994A (ja) 2006-12-14
US20100330031A1 (en) 2010-12-30
HK1084150A1 (en) 2006-07-21
DE602004015995D1 (de) 2008-10-02
EP1897938B1 (en) 2010-10-06
US7790445B2 (en) 2010-09-07
CN1826410A (zh) 2006-08-30
WO2005007857A1 (en) 2005-01-27
PT1649023E (pt) 2008-11-20
EP1649023B1 (en) 2008-08-20
US8226954B2 (en) 2012-07-24
KR20060040697A (ko) 2006-05-10
US20070264235A1 (en) 2007-11-15
CA2532783C (en) 2013-09-17
JP4672659B2 (ja) 2011-04-20
AU2004257935A1 (en) 2005-01-27
ES2311831T3 (es) 2009-02-16
IL173158A0 (en) 2006-06-11
DK1649023T3 (da) 2008-10-06
CA2532783A1 (en) 2005-01-27
EP1897938A1 (en) 2008-03-12
US20100330051A1 (en) 2010-12-30
IL173158A (en) 2009-12-24

Similar Documents

Publication Publication Date Title
CY1110397T1 (el) Πολυπεπτιδιο που εχει βελτιωμενη δραστικοτητα αποαμινασης κυτοσινης
IL267186B (en) Regulatory t-cell epitopes, their preparations and uses
ATE462000T1 (de) Verfahren zur herstellung von l-arginin, l- ornithin oder l-citrullin
ATE417595T1 (de) Keratin-bindende polypeptide
BRPI0517493A (pt) polinucleotìdeo isolado, promotor vetor de expressão, célula hospedeira e uso de um polinucleotìdeo
BRPI0307702B8 (pt) formulações de solução contendo anticorpo
MA31997B1 (fr) Nouveaux derives de l'insuline presentant un profil d'action extremement retarde
DE602006019050D1 (de) Polypeptide mit cellobiohydrolaseaktivität und dafür kodierende polynukleotide
DK1654355T3 (da) Pseudomonas polypeptidvarianter med ikke-maltogen exoamylaseaktivitet og deres anvendelse til fremstilling af fødevarer
ATE408624T1 (de) Verfahren zur reinigung von fsh
EA201170878A1 (ru) Полипептиды с ксиланазной активностью
DK1601776T3 (da) Ekspressionsvektorer omfattende mCmV-IE2-promotoren
DE602005020815D1 (de) Verändertes vp-1capsidprotein von parvovirus b19
DE60322613D1 (de) Frostschutzproteine aus Basidiomyceten
RS51325B (sr) Polipeptidi koji imaju antimikrobno dejstvo i polinukleotidi koji ih kodiraju
DE60335549D1 (de) Gewinnung von Hitzeschockproteinen
SG146640A1 (en) Isolated photoprotein mtclytin, and use thereof
CY1109904T1 (el) Προαγωγεας της il-18bp, η παρασκευη και χρηση του
DE602007006493D1 (de) Peptide mit proliferationshemmender wirkung
MY150639A (en) T cell adhesion molecule and antibody thereto
ATE496121T1 (de) Lactobacillus fermentum n-desoxyribosyl- transferasen und deren verwendung zur enzymatischen synthese von 2',3'- didesoxynucleosiden und 2',3'-didehydro-2',3'- didesoxynucleosiden
SE0101519D0 (sv) Nucleic ACID
EP1467207A4 (en) SCREENING PROCESS
TW200617021A (en) Isolated photoprotein aequorin y89f, and its use
WO2006122650A3 (de) Isoliertes photoprotein aqdecay sowie dessen verwendung